Loading patent…
AssigneeFundacio Institut D'Investigacio Biomedica De Bellvitge (Idibell)
InventorsJosep M. Aran Perramon, Luis Antonio Ruiz Avila, Jordi Ortiz Sagrista, Nuria Lluch Lafuente
Estimating the term…
Compounds for use in the prevention and/or treatment of immunological diseases, particularly rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis, are described, characterized by the subcutaneous administration of isoforms of C4BP lacking the beta chain or polypeptides comprising the CCP6 region of the alpha chain of C4BP no more than once a week or at a dose ranging from 0.24 mg/m2 to 9.99 mg/m2. Pharmaceutical compositions comprising from 0.45 mg to 18.90 mg of these compounds for the prevention and/or treatment of these diseases are also described.
A method for the treatment of an immunological disease caused by an undesired activation of the immune system by increasing tolerogenic dendritic cell and/or regulatory T cell populations in a subject in need thereof comprising administering to said subject:
A method for the treatment of an immunological disease caused by an undesired activation of the immune system by increasing tolerogenic dendritic cell and/or regulatory T cell populations in a subject in need thereof comprising administering to said subject of a pharmaceutical composition comprising from 0.45 mg to 18.90 mg of:
Dependencies are inferred from the claim text.